NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01251107,Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma,https://clinicaltrials.gov/study/NCT01251107,,COMPLETED,"The choice of a preferred first-line treatment requires balancing the desire for optimal disease control with the occurrence of early and late treatment-related effects. To fully assess this balance, the treatment decision process should ideally take into account the outcome following a consistent second-line therapy, in particular when tolerated, widely applicable and highly effective salvage regimens exist, like in Hodgkin lymphoma failing initial chemotherapy.",NO,Hodgkin Lymphoma,DRUG: Bleomycin|DRUG: Etoposide|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Vincristine|DRUG: Procarbazine|DRUG: Prednisone|DRUG: Doxorubicin|DRUG: Bleomycin|DRUG: Vinblastine|DRUG: Dacarbazine,"Freedom from first progression at 5 years, After a median of 5 years from start of the study","Freedom from second progression at 5 years, After a median of 5 years from start of protocol|Overall survival at 5 years, After a median of 5 years from start of the protocol|Number of participants with acute adverse events at initial therapy and at salvage therapy as a measure of safety and tolerability, After 3 months from last intervention|Number of participants long term sequelae, Number of participants who developed leukemia Number of participants who developed solid tumors Number of participants who developed cardiovascular disease, After a median of 10 years",,Fondazione Michelangelo,,ALL,"CHILD, ADULT",PHASE3,331,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,41/99,2000-03,2009-11,2009-11,2010-12-01,,2015-08-13,"Fondazione IRCCS Istituto Nazionale di Tumori di Milano, Milano, Italy",
